Hostname: page-component-cd9895bd7-q99xh Total loading time: 0 Render date: 2024-12-27T22:17:31.108Z Has data issue: false hasContentIssue false
  • English
  • Français

Smokers’ Treatment Expectancies Predict Smoking Cessation Success

Published online by Cambridge University Press:  27 August 2014

Lisa M. Fucito ,
Benjamin A. Toll ,
Corey R. Roos  and
Andrea C. King
Lisa M. Fucito*
Affiliation:
Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA
Benjamin A. Toll
Affiliation:
Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA Yale Cancer Center, New Haven, CT, USA Yale-New Haven Hospital, New Haven, CT, USA
Corey R. Roos
Affiliation:
Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA Department of Psychology, University of New Mexico, Albuquerque, NM, USA
Andrea C. King
Affiliation:
Department of Psychiatry & Behavioral Neuroscience, University of Chicago, Chicago, IL, USA
*
Address for correspondence: Lisa M. Fucito, Department of Psychiatry, Yale University School of Medicine, 1 Long Wharf Drive, Box 18, New Haven, CT 06511, USA. Email: lisa.fucito@yale.edu
Get access Rights & Permissions [Opens in a new window]

Abstract

Introduction: Smokers’ treatment expectancies may influence their choice of a particular medication as well as their medication experience.

Aims: This study examined the role of smokers’ treatment expectancies to their smoking cessation outcomes in a completed, randomized, placebo-controlled trial of naltrexone for smoking cessation, controlling for perceptions of treatment assignment.

Methods: Treatment-seeking cigarette smokers (N = 315) were randomized to receive either naltrexone (50 mg) or placebo in combination with nicotine patch and behavioural counselling. Expectancies for naltrexone as a smoking cessation aid were assessed at baseline and four weeks after the quit date.

Results: More positive baseline medication expectancies predicted higher quit rates at one month in the naltrexone group (OR = 1.45, p = 0.04) but were associated with lower quit rates in the placebo group (OR = 0.66, p = 0.03). Maintaining and/or increasing positive medication expectancies in the first month of treatment was associated with better pill adherence during this interval in the naltrexone group (ps < 0.05). Positive baseline medication expectancies were also associated with the perception of having received naltrexone over placebo among all participants.

Conclusions: Positive medication expectancies in smokers may contribute to better treatment response. Assessing treatment expectancies and attempting to maintain or improve them may be important for the delivery, evaluation, and targeting of smoking cessation treatments.

Type
Original Articles
Information
Journal of Smoking Cessation , Volume 11 , Issue 3 , September 2016 , pp. 143 - 149
Copyright
Copyright © The Author(s), published by Cambridge University Press on behalf of Australian Academic Press Pty Ltd 2014 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Ajzen, I. (1991). The theory of planned behavior. Organizational Behavior and Human Decision Processes, 50 (2), 179.Google Scholar
Bandura, A. (1977). Self-efficacy: Toward a unifying theory of behavioral change. Psychological Review, 84 (2), 191–215.CrossRefGoogle Scholar
Bansal, M., Cummings, K. M., Hyland, A., & Giovino, G. (2004). Stop-smoking medications: Who uses them, who misuses them, and who is misinformed about them? Nicotine & Tobacco Research, 6 (6), 303–310.Google Scholar
Centers for Disease Control. (2013). Prevalence of current smoking among adults aged 18 and over: United States, 1997–2012. Retrieved July 30, 2013. http://www.cdc.gov/tobacco/data_statistics/mmwrs/byyear/2014/mm6302a2/intro.htm Google Scholar
Cox, L. S., Tiffany, S. T., & Christen, A. G. (2001). Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings. Nicotine & Tobacco Research, 3 (1), 7–16. doi: 10.1080/14622200020032051 Google Scholar
Cummings, K. M., Hyland, A., Giovino, G., Hastrup, J., Bauer, J., & Bansal, M. (2004). Are smokers adequately informed about the health risks of smoking and medicinal nicotine? Nicotine & Tobacco Research, 6 (6), 333–340.CrossRefGoogle ScholarPubMed
Etter, J. F., & Perneger, T. V. (2001). Attitudes toward nicotine replacement therapy in smokers and ex-smokers in the general public. Clinical Pharmacology & Therapeutics, 69 (3), 175–183.Google Scholar
Ferguson, S. G., Gitchell, J. G., Shiffman, S., Sembower, M. A., Rohay, J. M., & Allen, J. (2011). Providing accurate safety information may increase a smoker's willingness to use nicotine replacement therapy as part of a quit attempt. Addictive Behaviors, 36 (7), 713–716.Google Scholar
Finniss, D. G., & Benedetti, F. (2005). Mechanisms of the placebo response and their impact on clinical trials and clinical practice. Pain, 114 (1–2), 3–6.CrossRefGoogle ScholarPubMed
Fiore, M., Jaén, C., Baker, T., Bailey, W. C., Benowitz, N. L., Curry, S. J., et al. (2008). Treating tobacco use and dependence: 2008 update. Public Health Service sponsored Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services.Google Scholar
Fucito, L. M., & Juliano, L. M. (2007). Effects of instructions on responses to the nicotine patch: A laboratory study. Psychopharmacology (Berl), 194 (4), 475–483.Google Scholar
Fucito, L. M., Toll, B. A., Salovey, P., & O’Malley, S. S. (2009). Beliefs and attitudes about bupropion: Implications for medication adherence and smoking cessation treatment. Psychology of Addictive Behaviors, 23 (2), 373–379.CrossRefGoogle ScholarPubMed
Hammond, D., McDonald, P. W., Fong, G. T., & Borland, R. (2004). Do smokers know how to quit? Knowledge and perceived effectiveness of cessation assistance as predictors of cessation behaviour. Addiction, 99 (8), 1042–1048.Google Scholar
Holmbeck, G. N. (2002). Post-hoc probing of significant moderational and mediational effects in studies of pediatric populations. Journal of Pediatric Psychology, 27 (1), 87–96.Google Scholar
Hutchison, K. E., Monti, P. M., Rohsenow, D. J., Swift, R. M., Colby, S. M., Gnys, M. et al. (1999). Effects of naltrexone with nicotine replacement on smoking cue reactivity: Preliminary results. Psychopharmacology (Berl), 142 (2), 139–143.CrossRefGoogle ScholarPubMed
Juliano, L. M., & Brandon, T. H. (2004). Smokers’ expectancies for nicotine replacement therapy vs. cigarettes. Nicotine & Tobacco Research, 6 (3), 569–574.Google Scholar
King, A. C., Cao, D., O’Malley, S. S., Kranzler, H. R., Cai, X., deWit, H. et al. (2012). Effects of naltrexone on smoking cessation outcomes and weight gain in nicotine-dependent men and women. Journal of Clinical Psychopharmacology, 32 (5), 630–636.Google Scholar
King, A. C., Cao, D., Vanier, C., & Wilcox, T. (2009). Naltrexone decreases heavy drinking rates in smoking cessation treatment: An exploratory study. Alcoholism: Clinical & Experimental Research, 33 (6), 1044–1050.Google Scholar
King, A. C., de Wit, H., Riley, R. C., Cao, D., Niaura, R., & Hatsukami, D. (2006). Efficacy of naltrexone in smoking cessation: A preliminary study and an examination of sex differences. Nicotine & Tobacco Research, 8 (5), 671–682.Google Scholar
King, A. C., Sánchez-Johnsen, L., Van Orman, S., Cao, D., & Matthews, A. K. 2008. A pilot community-based intensive smoking cessation intervention in African Americans: Feasibility, acceptability, and early outcome indicators. Journal of the National Medical Association, 100, 208–217.Google Scholar
Kirsch, I. (1985). Response expectancy as a determinant of experience and behavior. American Psychologist, 40 (11), 1189–1202.Google Scholar
Kirsch, I. (1997). Specifying nonspecifics: Psychological mechanisms of placebo effects. In: A. Harrington (Ed.) The placebo effect: Interdisciplinary explorations (pp. 166–186). Cambridge, MA: Harvard University Press.Google Scholar
Krishnan-Sarin, S., Meandzija, B., & O’Malley, S. (2003). Naltrexone and nicotine patch in smoking cessation: A preliminary study. Nicotine & Tobacco Research, 5 (6), 851–857.Google Scholar
Mooney, M. E., Leventhal, A. M., & Hatsukami, D. K. (2006). Attitudes and knowledge about nicotine and nicotine replacement therapy. Nicotine & Tobacco Research, 8 (3), 435–446.Google Scholar
Ockene, J. K., Emmons, K. M., Mermelstein, R. J., Perkins, K. A., Bonollo, D. S., Voorhees, C. C. et al. (2000). Relapse and maintenance issues for smoking cessation. Health Psychology, 19, 17–31.Google Scholar
O’Malley, S. S., Cooney, J. L., Krishnan-Sarin, S., Dubin, J. A., McKee, S. A., Cooney, N. L. et al. (2006). A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation. Archives of Internal Medicine, 166 (6), 667–674.Google Scholar
O’Malley, S. S., Krishnan-Sarin, S., McKee, S. A., Leeman, R. F., Cooney, N. L., Meandzija, B. et al. (2009). Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation. International Journal of Neuropsychopharmacology, 12 (5), 589–597.Google Scholar
Robinson, J. D., Lam, C. Y., Carter, B. L., Wetter, D. W., & Cinciripini, P. M. (2012). Negative reinforcement smoking outcome expectancies are associated with affective response to acute nicotine administration and abstinence. Drug & Alcohol Dependendence, 120 (1–3), 196–201.Google Scholar
Schnoll, R. A., Epstein, L., Audrain, J., Niaura, R., Hawk, L., Shields, P. G. et al. (2008). Can the blind see? Participant guess about treatment arm assignment may influence outcome in a clinical trial of bupropion for smoking cessation. Journal of Substance Abuse Treatment, 34 (2), 234–241.CrossRefGoogle Scholar
Shiffman, S., Ferguson, S. G., Rohay, J., & Gitchell, J. G. (2008). Perceived safety and efficacy of nicotine replacement therapies among US smokers and ex-smokers: Relationship with use and compliance. Addiction, 103 (8), 1371–1378.Google Scholar
Sobell, L. C., & Sobell, M. B. (1992). Timeline follow-back: A technique for assessing self-reported alcohol consumption. In Litten, R. Z. & Allen, J. P. (Eds.), Measuring alcohol consumption: Psychosocial and biochemical methods (pp. 41–72). Totowa, NJ: Humana Press.CrossRefGoogle Scholar
Tate, J. C., Stanton, A. L., Green, S. B., Schmitz, J. M., Le, T., & Marshall, B. (1994). Experimental analysis of the role of expectancy in nicotine withdrawal. Psychology of Addictive Behaviors, 8 (3), 169–178.CrossRefGoogle Scholar
Thomas, J. L., Guo, H., Lynam, I. M., Powell, J. N., Okuyemi, K. S., Bronars, C. A. et al. (2008). The impact of perceived treatment assignment on smoking cessation outcomes among African-American smokers. Journal of General Internal Medicine, 23 (9), 1361–1366.Google Scholar
Vogt, F., Hall, S., & Marteau, T. M. (2008). Understanding why smokers do not want to use nicotine dependence medications to stop smoking: Qualitative and quantitative studies. Nicotine & Tobacco Research, 10 (8), 1405–1413.Google Scholar
Vogt, F., Hall, S., & Marteau, T. M. (2010). Examining why smokers do not want behavioral support with stopping smoking. Patient Education & Counseling, 79 (2), 160–166.Google Scholar
Vogt, F., & Marteau, T. M. (2012). Perceived effectiveness of stop smoking interventions: Impact of presenting evidence using numbers, visual displays, and different timeframes. Nicotine & Tobacco Research, 14 (2), 200–208.Google Scholar
Walsh, Z., Epstein, A., Munisamy, G., & King, A. (2008). The impact of depressive symptoms on the efficacy of naltrexone in smoking cessation. Journal of Addictive Diseases, 27 (1), 65–72.Google Scholar
Zbikowski, S. M., Jack, L. M., McClure, J. B., Deprey, M., Javitz, H. S., McAfee, T. A. et al. (2011). Utilization of services in a randomized trial testing phone- and web-based interventions for smoking cessation. Nicotine & Tobacco Research, 13 (5), 319–327.Google Scholar